The market lost $6 billion overnight! Beida is questioned again, the daily rise is "the penultimate"

Guide: The stock market fell due to the delay in reply to the Shenzhen Stock Exchange inquiry the opening price of The Day Beida Pharmaceuticals continued to fall as of the morning point formally stopped reporting the overall net outflow of yuan funds market value loss of 100 million yuan from the market value of 100 million to the bottom of the 100 million pharmaceutical manufacturing industry growth ranked firstAnalysis of its reasons The author believes that the big probability comes from the month-long Beida Pharmaceuticalres re-receiving Shenzhen Stock Exchange inquiry letter to ask whether the sale of the shares held by Zhejiang Bayda Pharmaceutical Technology Co., Ltd("Kaiming Innovation") to Ningbo Kaiming Innovation Technology Co., Ltd(hereinafter referred to as "the target company") is related to the content of the announcement, and requires that the relevant explanatory materials are submitted to my Department and disclosed to the public before the monthAs of today, Beida did not promptly release the response to the inquiry letter, resulting in a billion dollars of outflows from Beida PharmaceuticalsThe phenomenon of the fall and stop triggered a wide spread of discussion on this netizen said: lenovo this month Beida was asked about the "first quarter profit adjustment" coupled with this time again asked "whether it is involved in the transfer of benefits" people can not help but wonder whether behind the surge in its share price is suspiciousAt the same time, Beida shareholders second-higher cashing in nearly 100 million is also the content of investment concernsBenefiting from the previous surge in performance Ofda Pharmaceuticals recently rose to a new high since the listing of the relevant price-earnings ratio, price-to-earnings ratio, price/effect ratio are showing a seriously high valuation situationAnd if you look closely at its related financial data, it will be found that The growth of Baeda's performance is not due to the improvement of core competitiveness, one can not help but doubt whether there is a serious "artificial" traces of seriousOf course, not all investors here have above doubt that most of them still face today's phenomenon of doubt and still have enough trust in Beida PharmaceuticalsCoupled with a beida Pharmaceuticals interactive platform said the company's projects to carry out the first-line, second-line treatment of non-small cell lung cancer related clinical studies are in an orderly manner to advance the second-line treatment plan this year completed data locked first-line treatment plan completed this year into the groupBoth products Ektini sales continue to release volumeEktinib has earned a good reputation in the market for non-small cell lung cancer target drugsBoth old and new markets seem to be performing better at this time most doubts may be selectively ignored in the face of strong powerPipeline layout gradually increase investment confidence burst, but in any case, Beida since the beginning of the year about yuan shares of the stock price to now double the stock price not only thanks to the "Ektini" a drug hit the world Beida Pharmaceuticals listed in the year to the end of the year Beida Pharmaceuticals contributed revenue of 100 million yuan, billion yuan, billion yuan accounted for the proportion of operating income in the year, and in almost all of the company's performance and revenue growth at the same timeAnd after years of increasing emphasis on innovative drugs and heavy products, Beida Pharmaceuticals seems to have gone through the early stages of supporting most of revenue from a single product is accelerating the establishment of a macromolecule drug pipeline-related drugs and research and development pipeline effective layout to make up for the short board of Beida Pharmaceuticals in the field of macromolecule innovative drugs, and perhaps the source of confidence among most investorsGood industry trends are expected to benefit from Friday's National Health Insurance Administration on biological products (including insulin) and traditional Chinese medicine collection work held a successful symposium is expected to expand the scope of biological products and traditional Chinese medicine band procurement of expanding the trend more certain short-term or will bring volatility However, China's overall production capacity of biological products is low and it is difficult to quickly upgrade its band procurement in the future is expected to focus on mainly in public hospitals channels sales of large sales and in the health insurance catalog of products blood products, vaccines and other short-term participation in the collection of the possibility is lower and traditional Chinese medicine collection more complex With the layout of the Beida Pharmaceutical research and development pipeline and the short-term impact of the launch of heavy biological products will not be too great But in the long run, the decline in gross margins may also mean that the rise in sales will have little impact on Beida's current product layout Summary in the short term in response to the risk of the Beida Pharmaceuticals should step up the release of inquiry letter reply is not surprising many speculation will have a clear answer tonight and the relevant investors will only have to wait patiently for the official response before reasonable control of the strategic layout In the long run, Beida's long-term approach to the "slow bull" is the way to go by as early as possible for the market schedule of heavyweight products in response to nearly a year and a half of valuation increases Otherwise, once the trust and enthusiasm of investment collapses, the market value collapse is not far away Recommended Reading: Quarterly China New Drug Declaration Dynamics! Singing, sunny, Beda, Howson.. Another new product! What is the real trick of Beida Pharmaceuticals, which has been approved for clinical success by a large single product? Beida Pharmaceuticals in the future can re-create brilliant to see nearly two or three years of three new drugs Beida pharmaceutical products single, research and development trapped start-up team parted ways.